1. Home
  2. TYRA vs PLPC Comparison

TYRA vs PLPC Comparison

Compare TYRA & PLPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TYRA
  • PLPC
  • Stock Information
  • Founded
  • TYRA 2018
  • PLPC 1947
  • Country
  • TYRA United States
  • PLPC United States
  • Employees
  • TYRA N/A
  • PLPC N/A
  • Industry
  • TYRA Biotechnology: Pharmaceutical Preparations
  • PLPC Water Sewer Pipeline Comm & Power Line Construction
  • Sector
  • TYRA Health Care
  • PLPC Industrials
  • Exchange
  • TYRA Nasdaq
  • PLPC Nasdaq
  • Market Cap
  • TYRA 812.7M
  • PLPC 656.4M
  • IPO Year
  • TYRA 2021
  • PLPC N/A
  • Fundamental
  • Price
  • TYRA $15.79
  • PLPC $138.52
  • Analyst Decision
  • TYRA Strong Buy
  • PLPC
  • Analyst Count
  • TYRA 5
  • PLPC 0
  • Target Price
  • TYRA $31.00
  • PLPC N/A
  • AVG Volume (30 Days)
  • TYRA 484.8K
  • PLPC 11.1K
  • Earning Date
  • TYRA 11-07-2024
  • PLPC 10-30-2024
  • Dividend Yield
  • TYRA N/A
  • PLPC 0.58%
  • EPS Growth
  • TYRA N/A
  • PLPC N/A
  • EPS
  • TYRA N/A
  • PLPC 6.65
  • Revenue
  • TYRA N/A
  • PLPC $572,200,000.00
  • Revenue This Year
  • TYRA N/A
  • PLPC N/A
  • Revenue Next Year
  • TYRA N/A
  • PLPC N/A
  • P/E Ratio
  • TYRA N/A
  • PLPC $20.84
  • Revenue Growth
  • TYRA N/A
  • PLPC N/A
  • 52 Week Low
  • TYRA $10.60
  • PLPC $109.01
  • 52 Week High
  • TYRA $29.60
  • PLPC $142.91
  • Technical
  • Relative Strength Index (RSI)
  • TYRA 35.04
  • PLPC 61.39
  • Support Level
  • TYRA $15.04
  • PLPC $130.91
  • Resistance Level
  • TYRA $16.51
  • PLPC $142.91
  • Average True Range (ATR)
  • TYRA 0.89
  • PLPC 4.13
  • MACD
  • TYRA 0.08
  • PLPC -0.11
  • Stochastic Oscillator
  • TYRA 14.96
  • PLPC 80.07

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).

About PLPC Preformed Line Products Company

Preformed Line Products Co is a designer and manufacturer of products and systems for constructing and maintaining overhead and underground networks for energy, telecommunication, cable operators, data communication, and other industries. In addition, it provides solar hardware systems and mounting hardware for a variety of solar power applications. Its products consist of Energy Products, Communications Products, and Special Industries Products. The company's majority of the revenue is derived from the sale of products in The Americas with operations also in PLP-USA, Europe, the Middle East and Africa, and Asia-Pacific. The revenue gets driven by Energy products which comprise protecting transmission conductors, spacers, spacer-dampers, and Stockbridge dampers.

Share on Social Networks: